Drug Profile
Somatropin biosimilar - USV
Alternative Names: Human growth hormone biosimilar - USVLatest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator USV
- Class Growth hormones; Hormonal replacements; Obesity therapies; Recombinant proteins
- Mechanism of Action Human growth hormone replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered Somatotropin deficiency
Most Recent Events
- 04 Sep 2017 Somatotropin biosimilar is still registered for Somatotropin deficiency (In children) in India (USV pipeline, August 2017)
- 12 May 2015 USV has patent protection for somatropin biosimilar in USA and European Union (USV product pipeline, May 2015)